Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2016-08-22 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2016年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2016 年半年度财务报告' which translates to '2016 Half-Year Financial Report'. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2016. The report explicitly states it is a half-year report and includes comprehensive financial data and analysis for that period. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is an annual report or a certification or announcement of a report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2016
2016-08-22 Chinese
董事会关于2016年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised in the first half of 2016 by Guangdong Taicheng Pharmaceutical Co., Ltd. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and disclosure of raised funds. The report includes specific financial figures on the amount raised, usage, changes in project funding, and compliance with disclosure requirements. It also contains tables detailing the investment projects, changes in fund usage, and project progress. The document is substantive, contains actual financial data, and focuses on the management and use of capital raised by the company. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is not an announcement of a report but the report itself, and it is not an annual or interim financial report, nor an audit or regulatory filing. Therefore, the appropriate classification is CAP.
2016-08-22 Chinese
关于第三届董事会第七次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the company's third board meeting, including approval of the 2016 half-year report, credit facility application, and a special report on the use of raised funds. It does not contain the full half-year financial report itself but references it as a separate document to be released on August 23, 2016. The document is short (1565 characters) and serves as a formal disclosure of board decisions rather than the financial report or detailed management discussion. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about board meeting resolutions and related approvals, not the actual interim report or financial statements.
2016-08-22 Chinese
2015年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2015 annual equity distribution (dividend) plan of Guangdong Taicheng Pharmaceutical Co., Ltd. It details the dividend amount per share, the record date, the ex-dividend date, and the method of dividend payment. It also references the approval of the dividend plan at the 2015 annual general meeting held on June 28, 2016. The document is relatively short (1566 characters) and serves as a formal announcement of the dividend distribution details rather than a full financial report or annual report. Therefore, it fits the category of a Notice of Dividend Amount (DIV).
2016-08-18 Chinese
关于全资子公司获得药品临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its wholly-owned subsidiary obtaining clinical trial approval certificates from the National Medical Products Administration. It includes risk warnings and regulatory compliance statements. The document is short (733 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an announcement of a regulatory approval event rather than a financial report or detailed filing. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2016-08-12 Chinese
关于变更投资者联系电子邮箱的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding a change in the investor contact email address. It contains no financial data, no discussion of financial results, no regulatory certifications, or meeting materials. It is a straightforward contact information update. The document length is only 537 characters, indicating it is a brief notice rather than a detailed report. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2016-08-09 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.